Rising prevalence of neurological disorders, especially neurodegenerative diseases is majorly enhancing the neuroprotective agents industry growth rate. Other contributing factors include rising average life spans, brain injuries due to road accidents, and traumatic & stroke central nervous system injuries will also boost the business growth.
Lack of particular treatment alternatives will offer immense opportunities for the industry players to increase their presence in the marketplace. However, stringent regulatory approvals, high failure rate of prospective drugs in clinical trials and high costs involved in research activities may negatively affect the neuroprotective agents market size.
The neuroprotective agents market is segmented on the lines of its drugs, treatment, and regional. The basis of drug the market is segmented into Cholinesterase inhibitors, NMDA Receptor Antagonists, Anti-inflammatory & Anti-apoptotic Agents, Neurotropic Factors, Mitochondrial Dysfunction Regulators, Metal Ion Chelators, Ion Channel Modulators, Free Radical Trappers, and Anti-excitotoxic Agents. Based on application the global neuroprotective agents market covers Alzheimer’s Disease, Multiple Sclerosis, Parkinson’s Disease, Ocular Degeneration (Retinal Disorders), Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease, Neuropathies, and Brain Injury. The neuroprotective agents market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, and Rest of World. Each geographic market is further segmented to provide market revenue for selected countries such as the U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
NeuroVive Pharmaceutical, Genervon Biopharmaceuticals, Allon therapeutics, Inc., BHR Pharma LLC, Ceregene, Neuren Pharmaceuticals, and Bionure Inc are among the major players in the global neuroprotective agents market share. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Neuroprotective Agents Market has been segmented as below:
Neuroprotective Agents Market, By Drugs
Neuroprotective Agents Market, By Treatment
Neuroprotective Agents Market, By Region
The report covers:
Report scope:
The scope of the report includes a detailed study of neuroprotective agents market with the reasons given for variations in the growth of the industry in certain regions.
The report covers a detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include NeuroVive Pharmaceutical, Genervon Biopharmaceuticals, Allon therapeutics, Inc., BHR Pharma LLC, Ceregene, Neuren Pharmaceuticals, and Bionure Inc. Company profile includes assigning such as company overview, product landscape, financial overview, and recent developments.
The top company reports are intended to provide our buyers with a snapshot of the industry’s most influential players.
Reasons to Buy this Report:
Customization:
We can offer you custom research reports as per client’s special requirements
Below are our New Reports :-
Laboratory Information Management System Market
Kitasamycin (CAS 69-23-8) Market
Josamycin (CAS 16846-24-5) Market
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Increasing prevalence of neurological disorders
4.2.2. Longer life spans
4.3. Restraints
4.3.1. Insufficient clinical research
4.3.2. Stringent regulatory approval
4.4. Opportunities
4.4.1. Increasing R&D
4.5. Challenges
4.5.1. High costs involved in developing the product
4.5.2. High failure rate in clinical trials
5. Neuroprotective Agents Market, By Drugs
5.1. Key Points
5.2. Cholinesterase inhibitors
5.3. NMDA receptor antagonists
5.4. Anti-inflammatory and anti-apoptotic agents
5.5. Neurotropic factors
5.6. Mitochondrial dysfunction regulators
5.7. Metal Ion Chelators
5.8. Ion channel modulators
5.9. Free radical trappers
5.10. Anti excitotoxic agents
5.11. Others
6. Neuroprotective Agents Market, By Treatment
6.1. Key Points
6.2. Alzheimer’s disease
6.3. Multiple sclerosis
6.4. Parkinson’s disease
6.5. Ocular degeneration (retinal disorders)
6.6. Amyotrophic lateral sclerosis (ALS)
6.7. Huntington’s disease
6.8. Neuropathies
6.9. Brain injury
6.10. Other disorders
7. Competitive Landscape
7.1. Introduction
7.2. Recent Developments
7.2.1. Mergers & Acquisitions
7.2.2. New Product Developments
7.2.3. Portfolio/Production Capacity Expansions
7.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
7.2.5. Others
8. Company Profile
8.1. NeuroVive Pharmaceutical
8.1.1. Company Overview
8.1.2. Product/Service Landscape
8.1.3. Financial Overview
8.1.4. Recent Developments
8.2. Genervon Biopharmaceuticals
8.2.1. Company Overview
8.2.2. Product/Service Landscape
8.2.3. Financial Overview
8.2.4. Recent Developments
8.3. Allon therapeutics, Inc.
8.3.1. Company Overview
8.3.2. Product/Service Landscape
8.3.3. Financial Overview
8.3.4. Recent Developments
8.4. BHR Pharma LLC
8.4.1. Company Overview
8.4.2. Product/Service Landscape
8.4.3. Financial Overview
8.4.4. Recent Developments
8.5. Ceregene
8.5.1. Company Overview
8.5.2. Product/Service Landscape
8.5.3. Financial Overview
8.5.4. Recent Developments
8.6. Neuren Pharmaceuticals
8.6.1. Company Overview
8.6.2. Product/Service Landscape
8.6.3. Financial Overview
8.6.4. Recent Developments
8.7. Bionure Inc.
8.7.1. Company Overview
8.7.2. Product/Service Landscape
8.7.3. Financial Overview
8.7.4. Recent Developments
The Neuroprotective Agents Market has been segmented as below:
Neuroprotective Agents Market, By Drugs
Neuroprotective Agents Market, By Treatment
Neuroprotective Agents Market, By Region
